araag2/HINT huggingface dataset:
Clinical trial NCT00405665 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: l-arginine, l-arginine
SMILES: [N]=O, [N]=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of CF as defined by two or more clinical features of CF and a documented
             sweat chloride concentration > 60 mEq/L and/or two well characterized disease causing
             CFTR gene mutations

          -  14 years of age and older at enrollment

          -  Clinically stable at enrollment

          -  Ability to comply with medication use, study visits and study procedures

          -  FEV1 % predicted > 40% < 80 % as calculated by reference equations

        Exclusion Criteria:

          -  Respiratory culture positive for: B. cepacia complex within past year or at screening

          -  Use of systemic corticosteroids within 30 days of screening

          -  Use of intravenous antibiotics or oral quinolones within 14 days of screening

          -  History of biliary cirrhosis, portal hypertension, or splenomegaly

          -  Other major organ dysfunction

          -  History of lung transplantation or currently on lung transplant list

          -  Supplemental oxygen therapy

          -  Oxygen saturation < 95 % on room air

          -  Positive pregnancy test at screening

          -  Investigational drug use within 30 days of screening

          -  History of alcohol, illicit drug or medication abuse within 1 year of screening

          -  Acute respiratory symptoms

          -  Inability to take any form of bronchodilator

          -  Wheezing at the time of study
Clinical trial NCT00672386 (phase 2, status: completed)
Conditions: diabetes mellitus, type 2, diabetes mellitus, endocrine system diseases, nutritional and metabolic diseases
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, E89.810, E89.820, E89.822, E36.8, E36.01, E36.11, E89.811
Drugs: jnj16269110, jnj16269110, jnj16269110, placebo, metformin
SMILES: COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1, COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1, COC(=O)[C@H](N1CCC(CC1)C1=CC=C(NC(=O)C2=CC=CC=C2C2=CC=C(C=C2)C(F)(F)F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of Type 2 Diabetes Mellitus and treated with a stable dose of metformin for at
             least 2 months

          -  Women must be postmenopausal or surgically incapable of childbearing or if sexually
             active, be practicing an effective method of birth control

          -  BMI between 25 and 45 kg/m2

          -  HbA1c between 7% and 10%, inclusive

          -  Fasting plasma glucose not exceeding 240mg/dL (13.3mmol/L)

        Exclusion Criteria:

          -  Diabetes other than type 2 diabetes mellitus

          -  Treatment with oral anti-diabetic agents (other than metformin) or insulin during the
             12 weeks before baseline visit

          -  History of intolerance or hypersensitivity to sulfonylurea or sitagliptin

          -  History of clinically significant gastrointestinal, hepatic or cardiovascular disease

          -  Active proliferative diabetic retinopathy

          -  History of diabetic gastroparesis

          -  concurrent use of systemic corticosteroid
Clinical trial NCT01569152 (phase 2, status: terminated)
Conditions: rheumatoid arthritis (ra)
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: mk-8457 100 mg, dose-matched placebo, methotrexate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis for at least 6 months prior to screening

          -  Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66
             count) and >= 6 tender joints (of 68 joint count)

          -  C-reactive protein blood level >0.9 mg/dL

          -  Anti-citrullinated protein antibody positive and/or rheumatoid factor positive at
             screening

          -  American College of Rheumatology Functional Class I, II, or III

          -  Received methotrexate for a minimum of 3 months prior to screening with a regionally
             appropriate stable weekly dose for at least 4 weeks prior to screening

          -  If using oral corticosteroids, the participant must be on a stable dose of 10 mg
             prednisone

          -  No history of either untreated, latent, or active tuberculosis prior to baseline

          -  Participants of reproductive potential must agree to remain abstinent or use 2
             acceptable methods of birth control

        Exclusion Criteria:

          -  Presence of inflammatory disease other than rheumatoid arthritis, including but not
             limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus,
             or Lyme disease

          -  Positive hepatitis B surface antigen or hepatitis C test result or the presence of
             Human immunodeficiency virus (HIV) infection

          -  HIV positive

          -  User of recreational or illicit drugs or has had a history (within the previous 2
             years) of drug or alcohol abuse or dependence

          -  Females of childbearing potential who are pregnant, intend to become pregnant, or are
             lactating;

          -  Severe opportunistic infection within 6 months prior to study start.
Clinical trial NCT00506077 (phase 2, status: completed)
Conditions: paranoid schizophrenia
ICD codes: F20.0
Drugs: mk0249, comparator: placebo (unspecified)
SMILES: CC1=NC2=CC=CC(=C2C(=O)N1C1=CC=C(OCCCN2CCCC2)C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is clinically stable, on current antipsychotic medication for at least 3
             months and current dose for 2 months

          -  Patient has a 6th grade reading level or better

          -  Females are not pregnant, and those who can have children agree to remain abstinent or
             use acceptable birth control throughout the study

          -  Patient has had a stable living arrangement for at least 3 months prior to study start

          -  Patient is in general good health based on screening assessments

          -  Patient has total Positive and Negative Syndrome Scale (PANSS) score between 36 and 75
             at screening and at the first baseline visit

          -  Patient has a Clinical Global Impressions - Severity (CGI-S) score less than or equal
             to 4 at screening and at the first baseline visit

        Exclusion Criteria:

          -  Patient has a major disease/disorder that may interfere with cognitive testing (such
             as mental retardation) and/or pose a risk upon study participation

          -  Patient has a history of head trauma with loss of consciousness greater than 15
             minutes

          -  Patient has had warfarin treatment, MAO inhibitors, clonazepam or clozapine within 1
             month of screening

          -  Patient has had ECT treatment within 6 months of screening

          -  Patient requires treatment with antihistamines or certain other medications listed in
             the protocol

          -  Patient has a history of liver disease that has been active within the last 2 years,
             or a history of cancer within the past 5 years

          -  Patient has a history of alcohol or drug dependence within the past year or alcohol or
             drug abuse within 3 months of screening
Clinical trial NCT00396578 (phase 2, status: completed)
Conditions: ventilator associated pneumonia, respiratory infection, tracheobronchitis
ICD codes: J06.9, J22, J47.0, J44.0
Drugs: aerosolized vancomycin or gentamicin
SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  be on mechanical ventilation greater than 3 days

          -  greater than or equal to 18 years of age survival greater than 14 days

          -  greater than 2 ccs of tracheal secretions/4 hours

        Exclusion Criteria:

          -  allergy to drugs, pregnancy
Clinical trial NCT00121628 (phase 2, status: completed)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: amg 706
SMILES: CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1
Eligibility criteria:

        Inclusion Criteria: - Histologically confirmed locally advanced or metastatic thyroid
        cancer - Measurable disease - Normal blood pressure (if history of hypertension, blood
        pressure must be controlled with medication) - Evidence of disease progression within 6
        months before starting study (for differentiated thyroid cancer subjects) - Evidence of
        disease progression within 6 months before starting study OR symptomatic disease (for
        medullary thyroid cancer subjects) - Not a candidate for surgical resection, external beam
        radiotherapy, radioiodine therapy, or other local therapy - At least 18 years of age
        Exclusion Criteria: - Undifferentiated/anaplastic thyroid cancer - Untreated or symptomatic
        brain metastases - Prior malignancy, unless cured with treatment and no evidence of disease
        for greater than or equal to 3 years before starting study (history of thyroid cancer, in
        situ cervical cancer, or basal cell cancer of skin are exceptions) - Myocardial infarction
        or any unstable cardiac condition (e.g., congestive heart failure, unstable angina) within
        1 year before starting study - Arterial thrombosis or deep vein thrombosis within 1 year
        before starting study
Clinical trial NCT00218543 (phase 2, status: completed)
Conditions: attention deficit disorder with hyperactivity, cocaine-related disorders
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1, F14.14, F14.180, F14.182, F14.188, F14.19, F14.24, F14.280
Drugs: atomoxetine
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Meets DSM-IV criteria for cocaine dependence and adult ADHD

          -  Describes cocaine as the primary drug of abuse

          -  Meets DSM-IV criteria for cocaine dependence

        Exclusion Criteria:

          -  Meets DSM-IV criteria for current Axis I psychiatric disorders that require a
             psychiatric intervention (except ADHD or substance abuse)

          -  Current major depression

          -  Unstable physical disorders that might make participation unsafe (e.g., uncontrolled
             high blood pressure and tachycardia [systolic blood pressure greater than 150 mm Hg,
             diastolic blood pressure greater than 90 mm Hg, or a sitting heart rate greater than
             100])

          -  Acute hepatitis (individuals with chronic mildly elevated transaminase levels of less
             than 2 or 3 times the normal limit are not excluded)

          -  Diabetes

          -  Coronary vascular disease, as indicated by a history or suspected by an abnormal
             electrocardiogram

          -  History of cardiac symptoms

          -  History of seizures

          -  Narrow angle glaucoma

          -  Use of monoamine oxidase inhibitors (MAOIs) within 2 weeks of starting treatment with
             atomoxetine

          -  Currently taking prescribed psychotropic medications

          -  Currently taking medications for the treatment of ADHD

          -  Known sensitivity to atomoxetine

          -  Current suicidal ideation or history of suicidal or homicidal behavior within 2 years
             prior to study entry

          -  Pregnant or breastfeeding

          -  Physiologically dependent on any drugs other than nicotine or marijuana

          -  History of schizophrenia, bipolar disorder, or other psychotic disorders

          -  Currently taking cough medicine (e.g., dextromethorphan) and/or albuterol
Clinical trial NCT00587431 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: gnrh (leuprolide), testosterone gel, docetaxel
SMILES: CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of prostate adenocarcinoma histologically confirmed at MSKCC or SKCCC.

          -  Patient must have a serum testosterone > 180 ng/dl.

          -  Karnofsky performance status (KPS)>_70%.

          -  Patients must have adequate organ function as defined by the following

          -  laboratory criteria:

          -  WBC >_ 3500/mm3

          -  ANC >_1500/mm3

          -  Platelet count >100,000/mm3

          -  Hemoglobin >8.0g/dL

          -  Creatinine <1.6mg/dl

          -  Total Bilirubin WNL (unless due to Gilbert's disease and other LFTs are WNL)

          -  SGOT and SGPT If alkaline phosphatase is _< 2.5 x ULN, any elevations in

          -  AST/ALT; OR if AST/ALT is _<1.5 x ULN, any elevation in alkaline phos

          -  Prior hormonal therapy is allowed as:

               1. Neoadjuvant treatment prior to radiation therapy or radical pmstatectomy,
                  provided that the total duration of therapy does not exceed 6 months (Proscar is
                  not considered a hormone therapy).

               2. One cycle of intermittent therapy up to a maximum exposure of 6 months (Proscar
                  is not considered a hormone therapy).

          -  Patients must be at least 18 years of age.

          -  Patients must have signed an informed consent document stating that they understand
             the investigational nature of the proposed treatment

        Exclusion Criteria:

          -  Clinically significant cardiac disease (New York Heart Association Class III/IV), or
             severe debilitating pulmonary disease.

          -  Uncontrolled serious active infection.

          -  Anticipated survival of less than 3 months.

          -  Active CNS or epiduraltumor

          -  Inability or unwillingness to comply with the treatment protocol, follow-up, or
             research tests

          -  Peripheral neuropathy >_ grade 3.

          -  Patients with a history of severe hypersensitivity reaction to drugs formulated with
             polysorbate 80.

          -  Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 6 months after completion of the
             treatment.

          -  Prior chemotherapy

          -  Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital,
             St. Johns's Wort (hypericum perforatum) and ketoconazole is prohibited.
Clinical trial NCT00077987 (phase 2, status: completed)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: su011248
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic colorectal cancer

          -  Failed selected cancer therapies in the past.

        Exclusion Criteria:

          -  Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than
             bevacizumab.
Clinical trial NCT00439192 (phase 2, status: terminated)
Conditions: overactive bladder, urinary incontinence
ICD codes: N32.81, N39.492, R32, R39.81, N39.498, L24.A2
Drugs: elb245, tolterodine
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Reason stopped: 
    side effect profile did not match expectations
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients at least 18 years of age

          -  Symptoms of OAB for a minimum of 3 consecutive months prior to study entry; severity
             of OAB (as defined by patient reported symptoms) for a minimum of one month prior to
             study entry

          -  Ability to use a toilet independently and without difficulty

          -  No treatment with any medication against OAB during the 4 weeks prior to study entry

          -  Written informed consent

        Exclusion Criteria:

          -  Breastfeeding women, pregnant women or women who intend to become pregnant during the
             study or women of childbearing potential who are sexually active and not practicing a
             highly reliable method of birth control

          -  Any local pathology, that might cause the bladder symptoms

          -  Significant stress urinary incontinence or mixed stress/urgency incontinence

          -  Any neurological disease affecting bladder function or muscle strength

          -  Patient history of any lower urinary tract surgery or previous pelvic irradiation

          -  Local administration of botulinum toxin within the last 9 months in the lower urinary
             tract

          -  Start or change of a behavioral bladder training program

          -  Post voiding residual volumes larger than 250ml or symptoms of clinically relevant
             bladder outlet obstruction

          -  Nocturial polyuria

          -  History of liver disease and/or impaired liver function

          -  Cholestasis

          -  Chronic alcohol or drug abuse

          -  Evidence of significantly impaired renal function (

          -  Diabetes mellitus (type I or II) with significant peripheral neuropathy and/or
             polyuria

          -  Inflammatory bowel disease such as Crohn's disease, or ulcerative colitis

          -  Uncontrolled narrow angle glaucoma

          -  Chronic use of carbamazepine or paracetamol

          -  Participation in any drug study in the preceding 3 months

          -  Concomitant treatment with strong CYP3A4 inhibitors

          -  History or evidence of relevant cardiovascular or cerebrovascular disorders
Clinical trial NCT01172756 (phase 2, status: terminated)
Conditions: hypertension, pulmonary, ventricular dysfunction, left
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: riociguat (bay63-2521), riociguat (bay63-2521), riociguat (bay63-2521), placebo
SMILES: COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment was only stopped after the statistical power of the study was reached and the study
    objectives could be met despite the premature discontinuation.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients with symptomatic pulmonary hypertension due to left
             ventricular diastolic dysfunction

        Exclusion Criteria:

          -  Types of pulmonary hypertension other than group 2.2 of Dana Point Classification
Clinical trial NCT00226239 (phase 2, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, cisplatin, cetuximab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Stage III-IVB head and neck cancer, all sites, including unknown primary tumors (bulky
             stage II (T2N0) lesions of the base of tongue or hypopharynx and patients with stage
             II nasopharyngeal cancer are also eligible) Prior to study entry the resectability and
             alternative treatment options will be determined by a team composed of an Ear, Nose,
             and Throat Surgeon, a Radiation Oncologist and a Medical Oncologist. Stage
             determination, optimal local treatment, and its timing according to this protocol will
             be determined at this evaluation. Unequivocal demonstration of distant metastasis (M1)
             confers ineligibility

          2. Histologically or cytologically confirmed diagnosis of squamous cell or poorly
             differentiated carcinomas, or WHO types I-III of the nasopharynx

          3. Unidimensionally-measurable disease is required (RECIST)

          4. No prior chemotherapy, biologic/molecular targeted therapy (including any prior
             therapy which specifically and directly targets the EGFR pathway), or radiotherapy for
             head and neck cancer

          5. Prior surgical therapy will consist only of incisional or excisional biopsy and organ
             sparing procedures such as debulking of airway compromising tumors or neck dissection
             in a patient with an existing primary tumor (Any non-biopsy procedure must have taken
             place > 4 weeks but < 3 months of initiating protocol treatment)

          6. ECOG PS 0 or 1; 7. Organ & marrow function per protocol criteria and 8. Age of >=18
             years

        Exclusion Criteria:

          1. History of severe allergic reactions attributed to docetaxel or compounds of similar
             chemical or biologic composition to docetaxel, or other drugs formulated with
             polysorbate 80

          2. Uncontrolled intercurrent illness or significant history of uncontrolled cardiac
             disease

          3. Receiving any other investigational agents

          4. No history of prior malignancy, with the exception of curatively treated squamous cell
             or basal carcinoma of the skin or in situ cervical cancer, or malignancy that has been
             treated with a curative intent with a 5-year disease-free survival

          5. Significant baseline sensory or motor neurologic deficits (> grade I neuropathy); 6.
             HIV-positive patients and 7. Prior severe infusion reaction to a monoclonal antibody.